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Abstract: The modification of CD4+ T cells with exogenous nucleic acids or proteins is a critical step 
in several research and therapeutic applications, such as HIV studies and cancer immunotherapies. 
However, efficient cell transfections are not always easily achieved when working with these 
primary hard-to-transfect cells. While the modification of T cells is typically performed by viral 
transduction or electroporation, their use is associated with safety issues or cytotoxicity. Vapor 
nanobubble (VNB) photoporation with sensitizing gold nanoparticles (AuNPs) has recently 
emerged as a new technology for safe and flexible cell transfections. In this work, we evaluated the 
potential of VNB photoporation as a novel technique for the intracellular delivery of 
macromolecules in primary human CD4+ T cells using fluorescent dextrans as model molecules. 
Our results show that VNB photoporation enables efficient delivery of fluorescent dextrans of 10 
kDa in Jurkat (> 60% FD10+ cells) as well as in primary human CD4+ T cells (± 40% FD10+ cells), 
with limited cell toxicity (> 70% cell viability). We also demonstrated that the technique allows the 
delivery of dextrans that are up to 500 kDa in Jurkat cells, suggesting its applicability for the delivery 
of biological macromolecules with a wide range of molecular weights. Altogether, VNB 
photoporation represents a promising technique for the universal delivery of macromolecules in 
view of engineering CD4+ T cells for use in a wide variety of research and therapeutic applications.  
Keywords: gold nanoparticles; vapor nanobubble; photoporation; T cells; intracellular delivery; 
macromolecules 
 
1. Introduction 
Adoptive T cell transfer represents a promising, emerging approach for cancer immunotherapy 
and HIV therapy [1]. The generation of adoptive T cells, such as chimeric antigen receptor (CAR) T 
cells, requires genetic engineering to make the cells more potent to recognize and kill tumor cells or 
HIV-infected cells [2–4]. Although CD8+ cytotoxic T lymphocytes (CTLs) are preferred for tumor 
targeting, CD4+ ‘helper’ T cells support and enhance CTL activity, and are therefore essential to create 
an efficacious antitumor environment [5,6]. Furthermore, the use of genetically modified CD4+ T cells 
is thoroughly investigated for different treatment modes of HIV-infected patients, including the 
adoptive transfer of CCR5-modified CD4+ T cells [7–11].  
For the generation of adoptive CD4+ T cells, the efficient intracellular delivery of genes (e.g. 
coding for CAR) or proteins (e.g. CRISPR/Cas9) is indispensable [12]. Indeed, the therapeutic benefit 
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of CD4+ T cells for some promising cancer immunotherapies [5] and functional cures for HIV 
infection [13] strongly relies on the efficient modification of their functionality. However, current 
delivery technologies for these hard-to-transfect T cells are associated with various limitations [14–
16]. Viral vectors typically yield high transduction efficiencies, but their use is expensive, labor-
intensive, and associated with significant safety issues [17,18]. While lipid-based and polymer-based 
nanoparticles can be safer alternatives, efficient transfection is often hindered by poor uptake, e.g., in 
blood and immune cells [14], limited endosomal escape [19,20], and delayed unpacking of the cargo 
molecules from the carriers in the cytosol [21]. In addition, these synthetic carriers can typically only 
be used with specific cargo molecules (e.g., nucleic acids) and cell types [22].  
In view of the limitations associated with viral and non-viral carriers, membrane-
permeabilization methods have received increasing attention for the transfection of cells in vitro or 
ex vivo, owing to their ability to deliver a broad variety of cargoes into a wide range of cell types 
[15,22]. Electroporation is frequently used for the in vitro or ex vivo delivery of different types of 
macromolecules [23,24]. However, high electric fields can result in a drastic decrease in cell viability; 
also, electroporation has been shown to substantially alter the T cell phenotype and reduce its 
therapeutic efficacy [25,26]. More recently, microfluidics approaches for transient mechanical 
membrane poration by cell squeezing were shown to enable the transfection of different cell types 
with limited cytotoxicity [27,28]. However, a practical limitation is that typically a new dedicated 
microfluidic chip needs to be developed for each cell type, as there is a strong correlation between 
cell size and transfection efficiency [22]. An emerging alternative transfection technology that offers 
wide applicability with limited cytotoxicity is vapor nanobubble (VNB) photoporation (Figure 1). 
 
Figure 1. Vapor nanobubble (VNB) photoporation procedure for delivery of macromolecules in T 
cells. (a) First, cationic plasmonic gold nanoparticles (AuNPs) are incubated with the cells, allowing 
them to adsorb to the negatively charged cell membrane. (b) Next, the macromolecules of interest are 
added to cells. (c) Upon nanosecond pulsed laser irradiation, VNBs arise from the cell-bound AuNPs. 
After all the thermal energy is consumed, the VNBs will collapse and the associated shock waves 
cause physical cell membrane poration. This allows the extracellular macromolecules to diffuse into 
the cell cytoplasm. 
The technique typically makes use of plasmonic gold nanoparticles (AuNPs), which absorb laser 
light and efficiently convert it into thermal energy [29,30]. When absorbing intense nanosecond or 
picosecond laser pulses, AuNPs are heated to high temperatures and cause an almost instantaneous 
evaporation of the water layer in contact with the AuNP surface. This in turn leads to the formation 
of water vapor nanobubbles (VNB) that emerge around these particles upon the absorption of a laser 
pulse. The VNB will expand up to several hundred nm until the thermal energy from the AuNP is 
consumed, after which the bubble violently collapses, producing pressure waves that can cause 
mechanical damage to neighboring structures, such as a cell membrane. The disruptive mechanical 
force of these VNBs can thus be used for efficient pore formation in cell membranes, allowing the 
intracellular delivery of biological macromolecules [31–33]. The applicability of the technique for the 
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transfection of different macromolecules in various cell types has been amply demonstrated, 
including siRNA in adherent tumor cells [34] and murine CD8+ T cells [35]. 
Based on the promising results obtained with murine T cells, we here explored the suitability of 
VNB photoporation for the intracellular delivery of macromolecules in human CD4+ T cells, using 
fluorescent dextrans as model molecules. Previous studies from our group already indicated that a 
good correlation is obtained in delivery efficiency for fluorescent dextrans and functional 
macromolecules, such as siRNA [34,35], motivating their use as model macromolecules. In-house 
synthetized AuNPs were first extensively characterized to ensure reproducible cell attachment and 
the generation of VNBs. Next, the VNB photoporation procedure was successfully optimized for the 
delivery of 10 kDa fluorescent dextrans (FD10) in Jurkat cells and primary human CD4+ T cells. We 
showed that by screening for different AuNP concentrations, VNB photoporation conditions were 
found that enable efficient delivery in > 60% of Jurkat cells and in up to 40% of primary CD4+ T cells, 
while maintaining high cell viability (> 70%). To demonstrate that VNB photoporation can be used to 
deliver even larger compounds, Jurkat cells were furthermore photoporated in the presence of 
dextrans up to 500 kDa (FD500), resulting in over 50% FD500-positive cells. In conclusion, these 
results demonstrate the potential of VNB photoporation for the efficient intracellular delivery of 
macromolecules in primary human CD4+ T cells, thereby providing a very promising basis for future 
research on the transfection of functional macromolecules in view of CD4+ T-cell engineering.  
2. Materials and Methods 
2.1. Synthesis and Characterization of 60 nm AuNPs 
The synthesis of AuNPs with a core size of 60 nm was performed by a two-step procedure, using 
the Turkevich method [36,37]. First, AuNP seeds were formed by adding 0.01 M of citrate solution 
(Sigma-Aldrich, Bornem, Belgium) to 0.2 mM of chloroauric acid (HAuCl4; Sigma-Aldrich, Bornem, 
Belgium) solution under rapid stirring and allowing this mixture to react for 30 minutes. Next, larger 
AuNPs were obtained by overgrowing these AuNP seeds by adding Au3+ ions and ascorbate solution 
at an equimolar concentration of 0.01 M. The dipolar localized surface plasmon resonance (LSPR) 
peak of the UV-VIS spectrum was controlled throughout this procedure by UV-VIS spectroscopy 
using a NanoDrop 2000c spectrophotometer (ThermoFisher, Rockford, IL, USA). The AuNP synthesis 
was stopped when the dipolar LSPR peak reached 536 to 545 nm, corresponding to an average 
diameter of 60 nm.  
After synthesis, the AuNPs were made cationic by functionalization with 
poly(diallyldimethylammonium chloride) solution (PDDAC; Sigma-Aldrich, Bornem, Belgium). A 
final concentration of 0.06 mg/mL of PDDAC was used, and the mixture was allowed to react 
overnight. To remove unattached PDDAC, the AuNPs were washed by centrifugation (5000 × g, 10 
minutes) and eventually diluted in ddH2O to a stock concentration of ~4 × 1010 AuNPs/mL. 
The resulting AuNPs were characterized using a combination of dynamic light scattering, UV-
VIS spectroscopy, electrodynamic modeling using the Mie theory, and transmission electron 
microscopy (TEM). For determination of the average zeta potential and hydrodynamic size, the initial 
AuNP stock was diluted 5 × or 10 × in ddH2O, transferred to a folded capillary Zetasizer cell (Malvern, 
Worcestershire, UK), and measured with the Zetasizer Nano ZS (Malvern, Worcestershire, UK) 
equipped with Dispersion Technology Software (DTS). By recording the AuNP extinction spectrum, 
the AuNP core size and concentration were estimated. Using the extinction of the AuNP solution (ε), 
which was measured at the maximal extinction wavelength, the AuNP concentration was estimated 
as follows in Equation (1) [38]: 
[𝐴𝑢𝑁𝑃] (
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑚𝐿
)  =  𝜀 / (𝑏 𝑥 𝜎𝜀)   (1) 
where ‘b’ is the optical path length (1 cm) and ‘σε’ (1.4044 × 10−10 cm2 at 538 nm) is the theoretical 
extinction cross-section for spherical particles, as calculated by the Mie theory [39]. Before every 
photoporation experiment, the zeta potential and UV-VIS spectrum of the AuNPs was measured. A 
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zeta potential value of at least + 30 mV was considered acceptable to ensure reproducible AuNP 
attachment to the cells.  
The stability of AuNPs in cell culture medium was analyzed by nanoparticle tracking analysis 
using a NanoSight LM10 instrument (Malvern, Worcestershire, UK). Prior to analysis, the AuNP 
stock was diluted 2000× in ddH2O or Jurkat culture medium, and injected into the sample chamber. 
Five movies of 60 seconds (25 frames/second) were recorded for each sample, performed in triplicate 
for each condition, and analyzed with the NTA Analytical Software version 2.3 (Malvern, 
Worcestershire, UK) to determine the mean hydrodynamic size (in nm) of the AuNPs in either cell 
culture medium or ddH2O. 
To verify the core size of the AuNPs, transmission electron microscopy (TEM) images were 
captured using a JEM 1400 plus transmission electron microscope (JEOL, Tokyo, Japan) at a voltage 
of 80 kV (VIB-UGent Transmission Electron Microscopy-Core facility). For preparation of the 
samples, one drop (~25 µL) of the AuNP stock was applied onto a formvar/C-coated hexagonal 
copper grid (EMS G200H-Cu), incubated for 20 minutes, and washed five times in ddH2O. Using the 
ImageJ software (FIJI, https://fiji.sc/), the AuNP core size distribution was determined.  
2.2. Detection of VNBs and Determination of VNB Generation Threshold 
For the generation and detection of VNBs, a homemade setup was used as previously described 
by Xiong et al. 2014 [34]. A pulsed laser, tuned at a wavelength of 561 nm (Opolette™ HE 355 LD, 
OPOTEK Inc, Carlsbad, CA, USA), with a pulse duration of 7 ns and a laser pulse frequency of 20 
Hz, was used to illuminate the AuNPs for the generation of VNBs. Due to the short lifetime of VNBs, 
an electronic pulse generator (BNC575, Berkeley Nucleonics Corporation, San Rafael, CA, USA) was 
used to synchronize the camera (EMCCD camera, Cascade II: 512, Photometrics, Tucson, AZ, USA) 
with the pulsed laser. By this means, dark-field images were recorded before, during, and after VNB 
formation upon the absorption of a single laser pulse. The energy of the laser pulses was measured 
by an energy meter (LE, Energy Max-USB/RS sensors, Coherent, Santa Clara, CA, USA). The stock of 
60 nm AuNPs (~4 × 1010 AuNPs/mL) was diluted 50 × in ddH2O, and the dilution was transferred to 
50 mm γ-irradiated glass-bottom dishes (MatTek Corporation, Ashland, MA, USA). AuNPs were 
allowed to sediment on the bottom of the dish and were subsequently imaged by dark-field 
microscopy. The generated VNBs were visible as bright dots on a black background as a result of 
light scattering. For determination of the VNB generation threshold, the number of visible VNBs 
within the laser irradiated region (150 µm diameter) was quantified for increasing laser pulse 
fluences. The VNB threshold, which was defined as the laser fluence for which 90% of the maximal 
number of VNBs is obtained, was determined using a Boltzmann fit of the number of VNBs in the 
function of laser pulse fluence. All the further experiments were performed at approximately twice 
the VNB threshold value to ensure effective VNB formation.  
2.3. Jurkat and Primary Human CD4+ T Cell Culture 
Jurkat cells (human T cell leukemia line) were obtained from the American Type Culture 
Collection (ATCC® TIB-152™). The cells were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% fetal bovine serum, 2 mM L-Glutamine and 100 µg/mL 
penicillin/streptomycin (GibcoBRL, Merelbeke, Belgium). The cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C, and the culture medium was renewed every 2 to 3 days.  
One day prior to VNB photoporation, primary CD4+ T cells were isolated from buffy coats of 
healthy donors, which were donated after informed consent (Red Cross, Ghent, Belgium). Briefly, 
peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrifugation 
with Lymphoprep (ELITech Group, Belgium), and subsequently used for CD4+ T cell isolation by 
negative selection (EasySep, Stemcell technologies, Canada) according to manufacturer’s protocol. 
Primary CD4+ T cells were kept in culture at 37 °C in a 5% CO2 atmosphere in complete RPMI 
medium 1640, as described above for Jurkat cells, supplemented with 50 U/ml IL-2 (PeproTech, 
United Kingdom). 
Crystals 2019, 9, x FOR PEER REVIEW 5 of 16 
 
2.4. Visualization of AuNP Attachment and Quantification of the Number of AuNPs Per Cell 
Jurkat (250 × 103 cells) or primary human CD4+ T cells (1 × 106 cells) were incubated at 37 °C for 30 
minutes with different concentrations of AuNPs. Unbound AuNPs were removed by a washing step 
via centrifugation (300 × g, 5 minutes) and resuspended in culture medium. Subsequently, a part of the 
cells (50–250 × 103 cells) was transferred to a glass-bottom 96-well plate (Greiner Bio-one, Frickenhausen, 
Germany). Visualization of the AuNP attachment to cells was performed using confocal reflection 
microscopy (C1si or C2, Nikon Benelux, Brussels, Belgium) with a 60 × water immersion lens (Plan Apo 
60×, NA 1.2, Nikon Benelux, Brussels, Belgium). AuNP scattering was obtained using a 560 nm diode 
laser (CVI Melles Grio, NM, USA). For visualization of the cell membrane and nucleus, CellMask Deep 
red membrane stain (Invitrogen, Waltham, USA) and Hoechst33342 (Invitrogen, Waltham, USA) were 
used, respectively. Both stains were diluted 1000× in culture medium, added to the cells, and incubated 
for 10 minutes at 37 °C. The cells were washed with culture medium and imaged using confocal 
(reflection) microscopy. Image processing included merging the different fluorescent or reflection 
images into a composite, using the ImageJ (FIJI) software. 
2.5. Delivery of FITC-Dextrans to Jurkat and Human CD4+ T Cells by VNB Photoporation 
For intracellular delivery of FITC-dextrans in Jurkat and primary human CD4+ T cells, the same 
protocol was used. The cells were first incubated with AuNPs, as described above, after which the 
unbound AuNPs were removed by washing with culture medium. After centrifugation (5 min, 300 × 
g), the cells were resuspended in culture medium containing FITC-labeled dextrans (Sigma-Aldrich, 
Bornem, Belgium) of 10 kDa (FD10), 150 kDa (FD150), or 500 kDa (FD500) at a final concentration of 
2 mg/ml. As the manufacturer states that all the FITC-dextrans are conjungated with a frequency of 
0.003 to 0.020 mol FITC per mol of glucose, an equal mass concentration implies equal fluorescence. 
After transfer to a 96-well plate, the cells were treated by pulsed laser illumination (I = 1.9 J/cm²) for 
the generation of VNBs and the intracellular delivery of FITC-dextrans. Immediately after laser 
treatment, cells were washed twice by centrifugation (300 × g, 5 minutes), and resuspended in culture 
medium. The cells were incubated at 37 °C, 5% CO2 for at least 2 hours prior to analysis of the 
percentage of FITC-dextran positive cells or cell viability.  
2.6. Evaluation of FITC-Dextran Delivery by Confocal Microscopy and Flow Cytometry 
FITC-dextran uptake was visualized by confocal microscopy (C1si, Nikon Benelux, Brussels, 
Belgium) using a 10x objective lens (Plan Apo, NA 0.45, Nikon Benelux, Brussels, Belgium). The FITC 
label, which was attached to the dextran chains, was excited using a 488 nm argon-ion laser (CVI 
Melles Grio, NM, USA). For quantification of the percentage of FITC-dextran positive cells, the cells 
were measured by flow cytometry using a CytoFlex (Beckman Coulter, Suarlée, Belgium) flow 
cytometer. At least 10,000 single cells were gated for each sample. Flow cytometry data were analyzed 
using FlowJo (Treestar Inc., Ashland, OR, USA) software.  
2.7. Cell Viability Assay 
The viability of Jurkat cells and primary human T cells was assessed two hours after VNB 
photoporation treatment using a CellTiter-Glo® luminescent cell viability assay (Promega, Leiden, 
The Netherlands), according to the manufacturer’s protocol. In short, 20 to 50 µL of the cells per well 
was transferred to an opaque 96-well plate, and an equal volume CellTiter-Glo® reagent was added 
to each well. The content of the plate was mixed for 5 to 10 minutes using an orbital shaker (100 rpm), 
after which the luminescent signal was allowed to stabilize for 10 minutes. The luminescent signal of 
each well was measured using a GloMax™ 96 luminometer (Promega, Leiden, The Netherlands). Cell 
viability for the different conditions was determined relatively compared to the untreated samples.  
2.8. Statistical Analysis 
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Data are given as mean value ± standard deviation (SD). Graphpad Prism 8 (La Jolla, CA, USA) 
software was used to perform all the statistical analyses. Differences with a p-value < 0.05 were 
considered significant.  
3. Results 
3.1. Physicochemical Characterization of 60 nm Cationic AuNPs 
Cationic plasmonic gold nanoparticles (AuNPs) with a core size of about 60 nm and coated with 
poly(diallyldimethylammonium chloride) (PDDAC) were used as photothermal sensitizers for 
forming membrane pores. The synthesis of these AuNPs was performed by the production of AuNP 
seeds, followed by overgrowing these seeds to the desired size and functionalization with the cationic 
polymer PDDAC. By UV-VIS spectroscopy, it was found that the AuNP extinction spectrum matched 
well with that of 60 nm AuNPs (Figure 2a), as calculated from Mie theory. This result was further 
confirmed by transmission electron microscopy (TEM) imaging of the AuNPs, finding an average 
core diameter of 58 ± 14 nm (Figure 2b,c). The AuNP hydrodynamic size and zeta potential was 
measured by dynamic light scattering (DLS) as well. A representative size and zeta potential 
distribution of the AuNPs are displayed in Figure 2d and Figure 2e, respectively. The AuNPs were 
found to have an intensity mean size of 113 ± 4 nm with a mean zeta potential of + 42 ± 2 mV. The 
colloidal stability of AuNPs was additionally measured in cell culture medium by nanoparticle 
tracking analysis (Figure 2f). AuNPs were diluted in either ddH2O or cell culture medium, and their 
hydrodynamic size was determined. The mean hydrodynamic size of AuNPs diluted in culture 
medium (127 ± 8 nm) was found to be slightly, but significantly larger compared to the size of AuNPs 
in ddH2O (112 ± 21 nm), which may be due to the formation of a protein corona. Importantly, the 
hydrodynamic size of AuNPs in culture medium was very uniform with no signs of aggregation.  
 
Figure 2. Characterization of 60 nm cationic AuNPs. (a) Normalized extinction spectrum of the 
synthetized AuNPs. The green line shows representative experimental data, as determined by UV-
VIS spectroscopy. The dashed grey line shows the simulated extinction spectrum of 60 nm AuNPs, as 
determined by the Mie theory. (b) Representative transmission electron microscopy (TEM) image of 
the AuNPs (scale bar = 0.5 µm). (c) AuNP size distribution, as derived from the TEM images. 
Representative size (d) and zeta potential (e) distribution of the AuNPs (in ddH2O) as determined by 
dynamic light scattering. (f) Stability of the AuNPs in ddH2O versus cell culture medium was 
determined by nanoparticle tracking analysis. The black lines represent the mean size ± SD (n = 3, 5 
technical replicates each). A two-tailed unpaired student’s T test was performed to determine 
statistical differences (* p < 0.05). 
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3.2. Determination of the VNB Generation Threshold 
Illumination of plasmonic AuNPs with a nanosecond pulsed laser will cause the AuNP to be 
heated, eventually leading to the formation of VNBs as the laser fluence (energy per unit area) 
increases [33,34]. VNB can be visualized by dark field microscopy as they increase the amount of light 
scattering during their lifetime. This is illustrated in the dark field image sequence in Figure 3a. Before 
application of the laser pulse, AuNPs are visible as small diffraction limited spots of light. 
Immediately after the application of a single laser pulse within the indicated circle, VNBs are visible 
as short-lived intense flashes of light, as indicated by the yellow arrowheads. After that, almost no 
visible particles remain in the irradiated area since AuNPs tend to fragment upon pulsed laser 
irradiation [40].  By counting the number of VNBs within the irradiated area as a function of the laser 
pulse fluence, the so-called VNB generation threshold can be determined, which is defined as the 
laser fluence at which 90% of the maximal number of VNBs is obtained. From the data in Figure 3b, 
the threshold laser fluence was determined to be 0.96 J/cm². To assure effective VNB generation and 
subsequent membrane poration, a laser fluence of 1.9 J/cm², i.e., about twice the VNB threshold 
fluence, was chosen for subsequent VNB photoporation experiments. 
  
Figure 3. Determination of VNB generation threshold for 60 nm AuNPs by dark-field microscopy. (a) 
Detection of VNBs arising from 60 nm AuNPs (in ddH2O) by dark field microscopy. The yellow 
dashed circle indicates the illuminated region with a diameter of 150 µm. Upon laser illumination (I 
= 1.97 J/cm²), different VNBs can be observed as bright white spots that are indicated with yellow 
arrowheads (scale bar = 50µm). (b) For determination of the VNB threshold, the number of bubbles 
was determined for increasing laser pulse fluences. The VNB threshold, which is defined as the laser 
pulse fluence at 90% of the asymptotic value of the Boltzmann fit, is indicated with the grey line. 
3.3. Visualization and Quantification of AuNP Attachment to Jurkat and Primary Human CD4+ T Cells 
The initial step in the VNB photoporation procedure consists of incubating cells with cationic 
AuNPs that will adsorb electrostatically to the negatively charged cell membrane, allowing them to 
induce membrane pores upon laser irradiation and VNB generation. Based on the light scattering 
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properties of AuNPs, the attachment of AuNPs to Jurkat and primary human T cells was visualized 
and subsequently quantified by confocal reflection microscopy. AuNPs were present on the cell 
membrane of both Jurkat (Figure 4a) and primary human T cells (Figure 4b). The number of cell-
attached AuNPs increases for increasing concentrations of AuNPs, typically ranging from one to six 
AuNPs/cell. This trend was observed for both Jurkat (Figure 4c) and primary human T cells (Figure 
4d), although substantially higher AuNP concentrations were necessary to obtain the same amount 
of cell-attached AuNPs for primary human T cells as compared to Jurkat cells.  
 
Figure 4. AuNP attachment to Jurkat (a,c) and primary human CD4+ T cells (b,d). Visualization of 
AuNPs attached to Jurkat (AuNP concentration: 8 × 107 AuNPs/mL) and primary T cells (AuNP 
concentration: 5 × 108 AuNPs/mL) by confocal reflection microscopy. AuNPs are color coded in yellow 
and indicated by white arrowheads. Cell membranes and nuclei are labeled with CellMask Deep Red 
stain (red) and Hoechst 33342 (blue), respectively (scale bar = 5µm). Quantification of the average 
number of AuNPs attached to Jurkat (c) (n = 3 images, 160–220 cells/image) or primary human T cells 
(d) (n = 3 images, 70–120 cells/image) in a function of AuNP concentration. 
3.4. Intracellular Delivery of FITC-Dextran 10 kDa into Jurkat Cells 
An initial experiment aimed to optimize the VNB photoporation procedure for the intracellular 
delivery of FD10 in Jurkat cells. The Jurkat human T cell line is commonly used as a model for hard-
to-transfect primary human T cells. FITC-dextran with a molecular weight of 10 kDa (FD10) was used 
as a model compound. The percentage of FD10-positive cells and cell viability were measured for 
three different AuNP concentrations (4, 8 and 16 × 107 AuNPs/ml), corresponding to ~1, 2, and 5 
AuNPs per cell on average. As the AuNP concentration increases, so does the percentage of FD10-
positive cells, as can be seen from the representative confocal microscopy images in Figure 5a and 
the quantitative flow cytometry data in Figure 5b. At the highest tested concentration of 16 × 107 
AuNPs/mL, over 80% of FD10-positive Jurkat cells are obtained. The average amount of FD10 per 
cell also increases with AuNP concentration, which is here expressed as the relative mean 
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fluorescence intensity (rMFI) compared to cells that were incubated with FD10 but without laser 
irradiation. Along with this increasing percentage of FD10-positive cells, a decreasing trend in cell 
viability was observed. To minimize cytotoxicity, an AuNP concentration of 4 × 107 AuNPs/mL (~1 
AuNP/cell) can be used for which > 60% of FD10-positive Jurkat cells are obtained with > 70% cell 
viability. 
 
 
Figure 5. Intracellular delivery of 10 kDa of FITC-dextran (FD10) in Jurkat cells by VNB 
photoporation. Jurkat cells were photoporated in the presence of FD10 after incubation with 
increasing concentrations of AuNPs, ranging from 4 × 107 to 16 × 107 AuNPs/mL, and illumination 
with a single laser pulse of 1.9 J/cm². Untreated cells, cells incubated with FD10 (FD10 ctrl), or only 
incubated with AuNPs (AuNP ctrl) are used as controls. (a) Confocal microscopy images of Jurkat 
cells after photoporation in the presence of FD10 (scale bar = 100µm). (b) Graph representing the 
percentage of FD10-positive cells ± SD and relative mean fluorescence intensity (rMFI) ± SD (n = 3; 
independent repeats), measured by flow cytometry. (c) Graph representing the cell viability ± SD (n 
= 4; independent repeats), as determined by a CellTiter-Glo® assay 2 h after laser irradiation. A one-
way ANOVA with Dunnett’s multiple comparison test was performed to determine statistical 
differences between the untreated sample and the other samples (ns = not significant, *p < 0.05, ****p 
< 0.0001). 
3.5. Intracellular Delivery of FITC-Dextran 10 kDa into Primary Human CD4+ T Cells 
Encouraged by the promising results for Jurkat cells, we took the next step and investigated the 
applicability of VNB photoporation for the intracellular delivery of macromolecules in primary 
human CD4+ T cells. Again, we started by screening the percentage of FD10-positive cells and 
cytotoxicity for different AuNP concentrations. The quantification of AuNP attachment to CD4+ T 
cells (Figure 4d) already indicated that higher AuNP concentrations were required to have a similar 
number of AuNP adsorbed to the cells. Therefore, AuNP concentrations ranging from 1 × 108 to 1 × 
109 AuNPs/ml were used for these photoporation experiments. Representative confocal images of 
photoporated cells are shown in Figure 6a, while quantitative flow cytometry results are shown in 
Figure 6b. As expected, an increasing percentage of FD10-positive cells was obtained for higher 
AuNP concentrations, with up to 80% FD10-positive cells for a concentration of 1 × 109 AuNPs/ml. Of 
course, higher percentages of FD10-positive cells come at the expense of higher toxicity as well 
(Figure 6c). This is also why the number of green cells seems to decrease in the confocal images when 
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the AuNP concentration exceeds 2.5 × 108 AuNP/ml. At a concentration of 2.5 × 108 AuNPs/ml, about 
40% FD10-positive cells were obtained with an acceptable cell toxicity of ~70%. Taken together, these 
experiments clearly show that VNB photoporation can be successfully used to deliver 10 kDa of 
dextran macromolecules in primary human CD4+ T-cells. 
 
 
Figure 6. Intracellular delivery of 10 kDa of FITC-dextran (FD10) in human CD4+ T cells by VNB 
photoporation. T cells were photoporated in the presence of FD10 after incubation with increasing 
concentrations of AuNPs, ranging from 1x108 to 1 × 109 AuNPs/mL, and irradiation with a laser 
fluence of 1.9 J/cm². Untreated cells, cells incubated with FD10 (FD10 ctrl), or cells incubated with 
AuNPs (AuNP ctrl) are used as controls. (a) Confocal microscopy images of T cells after 
photoporation in the presence of FD10 (scale bar = 100 µm). (b) Graph representing the percentage of 
FD10-positive cells ± SD and relative mean fluorescence intensity (rMFI) ± SD (n = 2; independent 
repeats), measured by flow cytometry. (c) Graph representing the cell viability ± SD (n = 2; 
independent repeats) after 2 h, as determined by a CellTiter-Glo® assay. A one-way ANOVA with 
Dunnett’s multiple comparison test was performed to determine statistical differences between the 
untreated sample and the other samples (ns = not significant, **p < 0.01, ****p < 0.0001). 
3.6. Intracellular Delivery of Higher Molecular Weight FITC-Dextrans into Jurkat Cells 
Above, we demonstrated the applicability of VNB photoporation for the efficient delivery of 10 
kDa FITC-dextrans in both Jurkat cells and primary human CD4+ T cells. To further assess the 
potency of the technique for the delivery of macromolecules even larger than 10 kDa, the delivery of 
FITC-dextrans with a molecular weight of 10 kDa (FD10), 150 kDa (FD150), and 500 kDa (FD500) into 
Jurkat cells was evaluated. Using an AuNP concentration of 16 × 107 AuNPs/mL and a laser fluence 
of 1.9 J/cm², 80%, 69%, and 53% FD-positive cells were obtained for FD10, FD150, and FD500, 
respectively (Figure 7b), indicating that the percentage of positive cells only moderately decreases 
with increasing FITC-dextran molecular weight. A more pronounced decrease is seen in the relative 
mean fluorescence intensity per cell (rMFI), as observed by both confocal microscopy images (Figure 
Crystals 2019, 9, x FOR PEER REVIEW 11 of 16 
 
7a) and quantitative flow cytometry data (Figure 7b). This is due to a combined effect of molecules 
becoming large compared to the pore size as well as slower molecular diffusion. 
 
Figure 7. Intracellular delivery of FITC-dextrans (FD) of increasing molecular weight in Jurkat cells. 
FITC-dextrans with a molecular weight of 10 (FD10), 150 (FD150), or 500 kDa (FD500) were delivered 
by VNB photoporation, using an AuNP concentration of 16 × 107 AuNPs/mL and laser fluence of 1.9 
J/cm². As controls, cells were incubated with the respective FITC-dextran without VNB treatment. (a) 
Confocal microscopy images of Jurkat cells photoporated in the presence of FD10, FD150, or FD500 
(scale bar = 100 µm). (b) Graph representing the percentage of FD-positive cells ± SD and relative 
mean fluorescence intensity (rMFI) ± SD (n = 2; independent repeats), measured by flow cytometry. 
A two-tailed unpaired student’s T test was performed to determine statistical differences (ns = not 
significant, ****p < 0.0001). 
4. Discussion 
The clinical success of adoptive T cell therapy, including the promising CAR T-cell therapies, 
strongly relies on the safe and efficacious engineering of T cells [2,41]. While viral vectors and 
electroporation are currently the preeminent transfection tools for T cells, these techniques are 
typically associated with several safety and cytotoxicity issues [15]. AuNP-sensitized VNB 
photoporation is an emerging approach for the safe and efficient intracellular delivery of 
macromolecules in a broad range of cell types [31,34,35,42,43]. Previously, our group and others 
already demonstrated the use of the technique for the delivery of macromolecules in murine CD8+ T 
cells [35,44], but so far, the applicability for primary human CD4+ T cells remained elusive. In this 
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study, we evaluated AuNP-sensitized VNB photoporation for the intracellular delivery of model 
macromolecules of increasing molecular weight in hard-to-transfect Jurkat and primary human CD4+ 
T cells. 
VNB photoporation demands a combination of pulsed laser irradiation and light-absorbing 
nanoparticles (e.g., AuNPs) attached to the cell membrane. For this purpose, 60 nm AuNPs were 
synthetized in-house and modified with a cationic coating to enable efficient attachment to the 
negatively charged cell membrane. These AuNPs remained stable in cell culture medium, 
presumably due to the formation of a protein corona, which resulted in a slight increase in 
hydrodynamic radius [45,46]. The VNB generation threshold of the synthetized AuNPs was 
determined to be 0.96 J/cm², which is in good agreement with previously reported work on 
comparable AuNPs and with similar photoporation equipment [33–35].  
Since the photoporation efficiency strongly depends on the ability of AuNPs to attach to the cell 
membrane, AuNP adsorption was visualized and quantified by confocal reflection microscopy. We 
found that after 30 minutes of incubation, the particles attached to the cell membrane surface without 
signs of internalization. This is to be expected, considering the impaired endocytic uptake in both 
Jurkat and primary T cells [35]. In addition, the quantification of AuNP attachment after AuNP 
incubation indicated that considerably higher AuNP concentrations were required for primary 
human CD4+ T cells (108–109 AuNPs/ml) as compared to Jurkat cells (4–16 × 107 AuNPs/ml) to obtain 
a similar number of cell-attached AuNPs. The attachment of cationic nanoparticles to the cell 
membrane is enabled primarily by ionic interaction with negatively charged cell membrane 
proteoglycans, such as heparan sulfate proteoglycans (HSPGs) [47–51]. Quiescent primary human 
CD4+ T cells, as used in this study, typically have very low and even undetectable amounts of HSPGs 
[52], making the attachment of cationic AuNP less likely.  
The human Jurkat suspension cell line is notoriously difficult-to-transfect and acts as a valid 
model for human primary T cell studies [53]. Therefore, the VNB photoporation procedure was first 
tested and optimized for macromolecular delivery in Jurkat cells using different AuNP 
concentrations. Fluorescent dextrans (FD) with a molecular weight of 10 kDa served as a model 
compound, corresponding to the size of several therapeutic molecules, such as small nucleic acids 
(e.g., antisense oligonucleotides, siRNA/miRNA) or peptides. However, it should be noted that next 
to the physical size, also the shape, architecture, and physicochemical properties of a therapeutic 
cargo are very relevant characteristics to consider for intracellular delivery [15]. Increasing 
photoporation efficiencies were found for increasing AuNP concentrations, both in terms of the 
percentage of FD10-positive cells and the amount of dextran molecules that was delivered per cell. 
However, as is typical for any delivery technology, higher efficiencies were associated with higher 
cytotoxicity as well. At an AuNP concentration of 4 × 107 AuNPs/ml (~1 AuNP/cell), a good balance 
was found between the percentage FD-positive cells (> 60%) and cell viability (> 70%). These results 
are in line with previous work from our group on murine cytotoxic T cells [35], and show that just a 
few AuNPs per cell are already sufficient to obtain efficient macromolecular delivery [54]. Following 
these promising results with 10 kDa dextrans in Jurkat cells, VNB photoporation was further 
evaluated for the delivery of dextrans with a molecular weight of 150 and 500 kDa, corresponding to 
a hydrodynamic diameter of respectively 17 nm and 31 nm. A wide range of therapeutically relevant 
cargoes are within this size range, including transcription factors, antibodies, and genome-editing 
nucleases [15]. Our results are in agreement with a previous study from our group on HeLa cells [55], 
and suggested that the VNB-induced pores can have a size of up to 30 nm, as inferred by the observed 
influx of 500 kDa dextrans. For the efficient delivery of cargoes of this size, the generated membrane 
pores should be big enough and remain open sufficiently long for these larger and slowly diffusing 
molecules to be able to reach the cell cytoplasm. In this regard, the observed decrease in relative 
fluorescence per cell, but high percentage of positive cells, for higher molecular weight dextrans is 
understandable.  
While human CD4+ T cells are well-known for their central role in antiviral immune responses, 
it is becoming clear that these ‘helper’ T cells are also required for the generation of an efficacious 
antitumor environment in therapeutic cell therapy [5,7]. Indeed, they have been shown to increase 
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the potency of in vivo adoptive T cell therapy [56–58]. Therefore, human CD4+ T cells serve as very 
relevant and interesting targets for therapeutic cell engineering. Unfortunately, quiescent primary 
human CD4+ T cells are notoriously hard-to-transfect and are resistant to many different 
conventional polymer-based and lipid-based transfection modalities [15]. By VNB photoporation, we 
successfully delivered 10 kDa dextrans in CD4+ T cells. The percentage FD10-positive cells again 
increased with increasing AuNP concentration at the expense of decreasing cell viability. Still, 40% 
FD10-positive cells could be obtained with a high level of cell viability (> 70%). However, it should 
be noted that future research on the transfection of functional macromolecules (e.g., siRNA or 
mRNA) should take into account the specific T-cell subtype [59] and activation state [56,60], as it can 
strongly influence the transfection outcome.  
Altogether, our findings here demonstrate the applicability of VNB photoporation for the safe 
and efficient intracellular delivery of model macromolecules in Jurkat and human CD4+ T cells. 
Primary human T cells, especially quiescent T cells, are considered hard-to-transfect with most of the 
currently available transfection methods. The successful delivery of fluorescent dextrans of up to 500 
kDa by VNB photoporation, as demonstrated here, paves the way for future research on the use of 
the technology for transfection of human CD4+ T cells with functional macromolecules, such as CAR-
T mRNA for adoptive T-cell therapy [3], CRISPR ribonucleoprotein complexes for CCR5 knock out, 
or antibodies for CD4 protein knockdown [61]. 
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